• Cleerly partnered with Allelica to launch a polygenic risk score test for coronary artery disease, targeting inherited predisposition to coronary plaque.
• The CLIA lab-developed saliva test uses Allelica’s multi-ancestry PRS technology, positioned for use across diverse and admixed populations.
• The test can be ordered standalone or alongside Cleerly’s AI-enabled coronary CT analysis, combining genetic risk assessment with plaque quantification.
• Cleerly expects US physician availability immediately, broadening its preventive cardiology offering beyond imaging-only workflows.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cleerly Inc. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.